Intrasalivary Thymic Carcinoma: A Case Report and Literature Review

Michał Kunc1 · Alexandra Kamieniecki2 · Grzegorz Walczak2 · Tomasz Nowicki3 · Bartosz Wasąg4 · Bogusław Mikaszewski5 · Dominik Stodulski5 · Wojciech Biernat1

Received: 13 September 2021 / Accepted: 10 November 2021 / Published online: 22 November 2021 © The Author(s) 2021

Abstract
Ectopic thymic carcinomas are rarely diagnosed in the thyroid gland, let alone in extrathyroid tissues. In the currently available literature, only five cases of extrathyroidal malignancies with thymic differentiation have been reported as arising in the major salivary glands. A 69-year-old female presented with a slow-growing palpable mass in the left parotid gland. Fine needle aspiration biopsy suggested metastatic cancer, whereas core needle biopsy revealed high-grade squamous cell carcinoma. The patient underwent left radical parotidectomy with selective ipsilateral lymph node dissection and subsequent radiation therapy. The surgical specimen was taken for histopathological examination. Microscopically, the tumor resembled thymic carcinoma. It was composed of large nests of squamoid cells with smooth contours, focally with a syncytial growth pattern, and accompanied by abundant lymphocytes with reactive lymphoid follicles. This appearance resembled a micronodular thymic carcinoma with lymphoid hyperplasia. Moreover, the tumor displayed expression of squamous markers (p40 and p63) and markers of thymic carcinoma (CD5 and CD117). Therefore, the final diagnosis of intrasalivary thymic carcinoma was rendered. The molecular analysis including next-generation sequencing demonstrated no variants of the strong, potential, or unknown clinical significance. The patient remains disease-free at 1-year follow-up. In the current case, we comprehensively present a clinical, microscopic, molecular, and radiological picture of CD5-positive squamous cell carcinoma of the parotid. We postulate that similar cases should be designated as intrasalivary thymic carcinoma analogically to similar thyroid tumors. Our case and the limited literature data indicate they should be distinguished from conventional squamous cell carcinoma of major salivary glands due to their rather favorable prognosis.

Keywords Thymic carcinoma · Squamous cell carcinoma · CD5 · CD117 · Immunohistochemistry · Parotid gland · Salivary gland · CASTLE

Introduction
Ectopic tumors demonstrating thymic epithelial differentiation are rare lesions and when they occur they mostly develop in the thyroid gland. The current WHO classification of thyroid tumors contains three entities: ectopic thymoma, spindle epithelial tumor with thymus-like differentiation (SETTLE), and intrathyroid thymic carcinoma (ITC) [1]. The latter, also known as carcinoma showing thymus-like elements (CASTLE), is a rare tumor probably arising from ectopic thymic tissue or embryological branchial pouch remnants [2]. The 3rd branchial pouch detaches from the pharynx and separates into the thymus and parathyroids. While both migrate downwards, the thymus migrates further where the two lobes meet in the midline above the heart [3]. In the thyroid, solid cell nests show a similar immunophenotype to thymic cells and may represent precursor lesions...
for the neoplasms with thymic differentiation [2]. Aberrant thymic tissue is occasionally seen in other areas of the head and neck region, predominantly in children [4]. The first three cases of thymus-like malignancies in the thyroid were initially described as “intranthyroid epithelial thymoma” in 1985 by Miyauchi et al. [5]. Later, in 1990, Chan and Rosai proposed an acronym CASTLE, to designate its resemblance to thymic carcinoma [6]. Other reported names include carcinoma showing thymus-like differentiation or features, and CD5-positive thyroid carcinoma. Intrathyroid thymic carcinoma is a rare tumor, but the available data suggests it has an overall indolent clinical course [7]. Extrathyroid malignancies with thymic differentiation are extremely rare and there have only been five cases of extrathyroid ectopic thymic tissue is occasionally seen in other areas of the head and neck region, predominantly in children [4].

Case Report

A 69-year-old Caucasian female presented with a slow-growing palpable mass in the left parotid gland that was present for the past few months. She had no other symptoms or comorbidities. A craniofacial magnetic resonance imaging revealed that in the superficial lobe of the left parotid gland, there was a well-defined, lobulated lesion bulging into the deep lobe that measured 27 × 37 × 38 mm. The lesion’s signal intensity in T2-weighted images was intermediate and in T1-weighted images, the intensity was homogenous and low. Early enhancement after intravenous contrast agent administration was seen, with features of contrast wash-out (wash-out ratio of 38%, enhancement curve type B) and a marked diffusion restriction (apparent diffusion coefficient of 0.60–0.67 × 10⁻³ mm²/s)—Fig. 1. Multiple enlarged, heterogenous lymph nodes in the II and VA groups on the left side were observed, with no contralateral lymphadenopathy. In the differential diagnosis of the salivary gland lesion, a lymphoproliferative process was considered (e.g., MALT lymphoma). Fine needle aspiration biopsy revealed the presence of sheets and small groups of pleomorphic epithelioid cells in the background of reactive lymphocytes (group VI according to the Milan system for reporting salivary gland cytopathology; Fig. 2). Subsequently a core needle biopsy was performed eventually leading to a diagnosis of an HPV-negative high-grade squamous cell carcinoma. Computed tomography of the chest and abdomen did not reveal any abnormalities. The patient underwent left radical parotidectomy with selective ipsilateral lymph node neck dissection (groups I–III, V). The facial nerve was partially infiltrated by the tumor and was resected during the procedure leading to facial palsy. Subsequently, the patient underwent radical radiation therapy and is currently free of the disease after 12 months of follow-up.

Histopathological Findings

Microscopic examination revealed non-keratinizing squamous cell carcinoma infiltrated by abundant lymphocytes. Tumor cells were cohesive and formed large nests with smooth contours, focally with a syncytial growth pattern and accompanied by abundant lymphocytes with reactive lymphoid follicles (Fig. 3A–C). Morphologically, the tumor resembled micronodular thymic carcinoma with lymphoid hyperplasia, a provisional subtype of thymic squamous cell carcinoma and, to a lesser extent, lymphoepithelioma-like carcinoma [8, 9]. Cancer cells showed positivity for squamous cell markers, p40 and p63 (Fig. 3D), and were negative for p16, NUT, neuroendocrine markers (synaptophysin, chromogranin, CD56), DOG-1, androgen receptor, and SOX-10. No mucin production was observed. Epstein-Barr encoding region (EBER) in situ hybridization was negative. The Ki-67 proliferative index was 30%. Due to the morphological similarities with thymic carcinoma, CD5 and CD117 stainings were performed (Fig. 3E, F). Both markers were expressed by cancer cells supporting the final diagnosis of intrasalivary thymic carcinoma (ectopic thymic carcinoma of the salivary gland). Metastasis was found in one of 69 removed lymph nodes and displayed similar morphology and immunophenotype to the primary tumor. The final pathological stage of the tumor was pT2N1 according to the 8th edition of the American Joint Committee of Cancer Staging Manual.

Molecular Analysis

Nucleic acids were extracted from formalin-fixed paraffin-embedded tumor tissue using Cobas DNA Sample Preparation Kit (Roche Diagnostics) and FormaPure XL RNA (Beckman Coulter). Illumina TruSight Oncology 500 (TSO500) hybrid-capture assay targeting 523 cancer-relevant genes was used for comprehensive genome profiling. Library sequencing was accomplished using a NextSeq550 instrument (Illumina, San Diego, CA), and the data were analyzed using the Clinical Genomics Workspace (Pie- rianDx). No variants of the strong, potential, or unknown clinical significance were detected.

Discussion

Most salivary gland tumors with squamoid morphology represent mucoepidermoid carcinomas or metastatic squamous cell carcinomas of the head and neck. Primary squamous...
cell carcinoma arising primarily in the salivary gland is very infrequent and has unfavorable outcomes, especially in elderly patients with nodal and/or distant metastases [10]. To our knowledge, thymic-like squamous cell carcinomas in the salivary glands were reported only five times in the currently available literature. We present the 6th case of this entity arising in the major salivary glands.

Intrathyroid thymic carcinoma is one of four intrathyroid tumors with thymic differentiation and is recognized in the WHO classification of tumors of endocrine organs along with ectopic thymoma, ectopic hamartomatous thymoma, and spindle-cell tumor with thymus-like differentiation [1]. Other than ectopic cervical thymoma, the thymic nature is not immediately apparent due to the lack of immunohistochemical, ultrastructural, or genotypic thymus-specific markers [6]. However, CD5 can be a valuable marker for diagnosing thymic-like neoplasms in the thyroid, although lack of expression does not entirely rule them out [11].

Fig. 1 Magnetic resonance imaging in the axial plane of the left parotid region. In the turbo spin-echo sequence in T2-weighted image (a), the tumor (marked by the arrows) has intermediate signal intensity, observed in hypercellular lesions. In the turbo spin-echo sequence in T1-weighted image (b), the signal intensity is low. In the delayed contrast-enhanced gradient-echo T1-weighted image (c), the lesion shows heterogeneous and circumferential enhancement. In diffusion-weighted image (d) a marked diffusion restriction is observed (0.60–0.67 × 10⁻³ mm²/s), also typical for hypercellular lesions. The enhancement curve (e) shows the lesion’s signal intensity change after contrast agent administration on a timeline (expressed in seconds); early enhancement is visible with wash-out of the contrast agent (enhancement curve type B with wash-out ratio of 38%, typically seen in Warthin tumor). On pictures f to h, the subsequent phases of the dynamic examination are presented: pre-contrast image (f), early, strong, almost homogeneous enhancement of the lesion (g), and the last phase of the dynamic examination (h). Asterisk marks the mandible.
The very first case of extrathyroid carcinoma with thymic-like features arising in the major salivary gland was reported in the parotid gland in a 55-year-old woman in 2017 [12]. Only one case was reported outside the parotid, in the sublingual gland of a 35-year-old man that presented with an ipsilateral neck mass and was first misdiagnosed as metastatic squamous cell carcinoma [13]. The summary of the previously published cases is presented in Table 1.

In intrathyroid thymic carcinoma, radical resection is the treatment of choice and the prognosis after surgery is rather favorable if this treatment is achieved [14]. Just like our patient, the other intrasalivary thymic carcinomas were treated with total parotidectomy with selective neck lymph node dissection and postoperative adjuvant radiotherapy [12, 13, 15].

While intrathyroid thymic carcinoma has a generally good prognosis and it is essential to differentiate it from other more aggressive tumors [5], they may also recur after long intervals [6]. Accordingly, all patients with a salivary counterpart were alive at the date of publication, but one patient had dissemination to the pleura which occurred 10 years after removal of the primary tumor [16]. In the current report, the observation time is short (12 months) and the patient is being periodically monitored. Nevertheless, the current very limited data suggest that ectopic thymic carcinomas developing in the salivary glands demonstrate biological behavior similar to their thyroid counterparts. Due to this reason we postulate to use the analogous nomenclature for these tumors (i.e. intrasalivary thymic carcinoma).

Pathologists are aware of the existence of thymic-like neoplasms in the thyroid; thus neoplasms with thymic features are frequently considered in the differential diagnosis of thyroid malignancies. On the other hand, intrasalivary thymic carcinomas are most likely underrecognized. In one case the diagnosis was established retrospectively 10 years after the primary diagnosis [16]. We postulate that CD5 and CD117 should be included in the immunohistochemical panel for squamous cell carcinomas and undifferentiated carcinomas of the major salivary glands with an unusual microscopic features, especially if they resemble thymic carcinomas morphologically. Both markers are reliable indicators of thymic differentiation in squamous cell carcinoma. Two large studies showed that their expression in pulmonary squamous cell carcinoma is extremely rare [17, 18], and co-expression of CD5 and CD117 was not observed at all [19]. Accordingly, Ito et al. reported 100% sensitivity of CD5 expression as a marker of intrathyroid thymic carcinoma/CASTLE [5]. There is no data regarding the frequency of CD5 and CD117 expression in salivary carcinomas and this issue should be investigated in future studies.

Moreover, due to the lymphocyte-rich stroma, intrasalivary thymic carcinoma may be confused with lymphoepithelial carcinoma, which occasionally develops in the salivary glands [20]. However, the latter is usually diffusely positive for EBER in situ hybridization and is CD5 and CD117 negative. Other neoplasms which should be considered in the differential diagnosis include various carcinomas with squamous differentiation including metastatic HPV-positive squamous cell carcinoma, high-grade mucoepidermoid carcinoma, and NUT carcinoma. In the current case, the tumor was negative for p16, mucicarmine, and NUT excluding these entities from the diagnostic consideration.

Fig. 2 Haematoxylin and eosin stained fine needle aspiration smears from the parotid tumor. Groups of pleomorphic, epithelioid cancer cells (A, B) in the lymphocytic background

 Springer
Nevertheless, one case of thymic carcinoma of the parotid was diffusely positive for p16 and negative for HPV DNA, which may represent a potential diagnostic pitfall [21].

The origin of intrasalivary thymic carcinoma remains elusive. It is unclear if these tumors represent thymic differentiation of salivary elements or development from ectopic thymic elements. Since the thymus is derived directly from the third pharyngeal pouch and migrates to the thorax during development, thymic tissue, and therefore also thymic tumors, can be found anywhere near its primary formation site and along its embryologic migration path [12]. Ectopic thymic elements were identified in various areas of the head and neck [22]. The molecular origin is also unclear. Comprehensive sequencing of 523 genes performed in the current case did not detect any significant variants. Similarly, sequencing of 143 cancer-related genes performed in the case described by Wong et al. revealed only germline variants of PPARG, BRCA2, and NOTCH1 [12]. Very recently, Ishikawa et al. performed whole-exome sequencing on their case and detected five nonsynonymous and splicing somatic mutations (FREM2 p.Val861Phe, CLK3 p.Phe376Leu, DLGAP1 p.Lys294Asn, NOX1 p.Val165Met, and PSG9 c.430+4A>T) [21]. If these molecular abnormalities are recurrent in intrasalivary thymic carcinomas remains to be elucidated in further studies.

**Conclusion**

Ectopic thymic carcinoma remains a rare diagnosis, but it may involve major salivary glands. CD5 and CD117 immunohistochemistry should be considered in squamous cell carcinomas and undifferentiated carcinomas involving the salivary glands, especially when a distant primary tumor is not clinically evident and they display morphologic resemblance to thymic carcinoma. Intrasalivary thymic carcinoma should be regarded as a separate entity and should be included in the differential diagnosis of major salivary gland tumors.
| References | Age [years] | Gender | Location   | Histology                                                                 | IHC                      | Radiology                                                                      | Stage       | Follow-up                                      |
|------------|-------------|--------|------------|---------------------------------------------------------------------------|--------------------------|--------------------------------------------------------------------------------|-------------|-----------------------------------------------|
| [13]       | 35          | Male   | Sublingual gland | Solid cell nests separated by fibrous septa containing lymphoplasmacytic infiltrate | CK AE1/AE3 (+) p63 (+) CD5 (+) CD117 (+) /− BCL2 (+) S100 (−) PAX8 (−) TIF-1 (−) Thyroglobulin (−) SOX-10 (−) Chromogranin (−) Synaptophysin (−) | Enlargement and enhancement of the posterior third of the right sublingual gland | pT1N1M0    | 24 months (NED)                               |
| [12]       | 55          | Female | Parotid gland  | Solid cell nests separated by fibrous septa containing lymphoplasmacytic infiltrate | p40 (+) p63 (+) CD5 (+) CD117 (+) | Well-margined solid mass, with moderate contrast-medium affinity, in the superficial parotid, extending to the deep parotid lobe and sternocleidomastoid muscle | pT1N1M0    | 12 months (NED)                               |
| [15]       | 43          | Male   | Parotid gland  | Solid cell nests separated by fibrous septa                                  | CK AE1/AE3 (+) p63 (+) CD5 (+) CD117 (+) | Round soft tissue mass in the parotid gland, showing uneven and mild to moderate enhancement | N/A         | 10 months (NED)                               |
| [21]       | 23          | Female | Parotid gland  | Solid nests and trabeculae separated by fibrous septa accompanied by lymphoplasmacytic infiltrate | CK AE1/AE3 (+) p40 (+) p63 (+) p16 (+) CD5 (+) CK5/6 (+) LMP-1 (−) | Tumor composed of a solid portion and a cystic portion showing a slight enhancement of the solid portion and an irregular enhancement of the cyst wall Dynamic-enhanced MRI showed a short peak time and a low washout ratio | pT3N2M0    | 13 months (NED)                               |
| [16]       | 69a         | Female | Parotid gland  | N/A                                                                      | CK 5/6 (+) CD5 (+) CD117 (+) p63 (+) p40 (+) | N/A                                                                       | pT1N2M0    | 120 months (recurred as pleural carcinomatosis treated with pembrolizumab) |
Funding  Not applicable (no external funding).

Data Availability  Not applicable.

Code Availability  Not applicable.

Declarations

Conflict of interest  The authors declare that they have no conflict of interest.

Ethical Approval  The study was performed following the 1964 Helsinki Declaration standards.

Consent to Participate  The study was performed according to the local guidelines of the Medical University of Gdańsk.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bai Y, Kakudo K, Jung CK. Updates in the pathologic classification of thyroid neoplasms: a review of the World Health Organization Classification. Endocr Relat Cancer 2007;14:137–151.

2. Reimann JDR, Dorfman DM, Nosé V. Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study. Am J Surg Pathol. 2006;30:994–1001.

3. Gordon J, Manley NR. Mechanisms of thymus organogenesis and morphogenesis. Development. 2011;138:3865–78.

4. Fukushima T, Suzuki S, Ohira T, Shimura H, Midorikawa S, Ohtsuru A, et al. Prevalence of ectopic intrathyroidal thymus in Japan: the Fukushima Health Management Survey. Thyroid. 2015;25:534–7.

5. Ito Y, Miyashita A, Nakamura Y, Miya A, Kobayashi K, Kakudo K. Clinicopathologic significance of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation: a collaborative study with member Institutes of the Japanese Society of Thyroid Surgery. Am J Clin Pathol. 2007;127:230–6.

6. Chan JKC, Rosal J. Tumors of the neck showing thymic or related branchial pouch differentiation: a unifying concept. Hum Pathol. 1991;22:349–67.

7. Lominska C, Estes CF, Neupane PC, Shnayder Y, TenNapel MJ, O’Neil MF. CASTLE thyroid tumor: a case report and literature review. Front Oncol. 2017. https://doi.org/10.3389/fonc.2017.00207.

8. WHO Classification of Tumours Editorial Board. Thoracic tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2021.

| References | Age [years] | Gender | Location | Histology | Radiology | Stage | Follow-up |
|------------|------------|--------|----------|-----------|-----------|-------|-----------|
| Current case | 69 | Female | Parotid gland | Solid cell nests accompanied by abundant lymphoplasma-cytic infiltrate with lymphoid follicles | Lesion mainly in the superficial parotid, bulging into the deep parotid and showing early enhancement | pT2N1M0 | 12 months (NED) |

| IHC | CK AE1/AE ( +) | CD5 ( +) | CD117 ( +) | p63 ( +) | p16 (−) | Synaptophysin (−) | CD56 (−) | DOG-1 (−) | AR (−) | SOX-10 (−) | NUT (−) | EBER (−) |
|-----|----------------|---------|-----------|---------|--------|-------------------|---------|---------|-------|----------|--------|--------|
9. Weissferdt A, Moran CA. Micronodular thymic carcinoma with lymphoid hyperplasia: a clinicopathological and immunohistochemical study of five cases. Mod Pathol. 2012;25:993–9.
10. Jo U, Song JS, Choi S-H, Nam SY, Kim SY, Cho K-J. Primary squamous cell carcinoma of the salivary gland: immunohistochemical analysis and comparison with metastatic squamous cell carcinoma. J Pathol Transl Med. 2020;54:489–96.
11. Ito Y, Miyauchi A, Nakamura Y, Miya A, Kobayashi K, Kakudo K. Clinicopathologic significance of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation. Am J Clin Pathol. 2007;127:230–6.
12. Wong EHC, Tetter N, Tzankov A, Muller L. CASTLE tumor of the parotid: First documented case, literature review, and genetic analysis of the cancer. Head Neck. 2018;40:E1–4.
13. Ardighieri L, Tomasoni M, Battocchio S, Facchetti F, Maroldi R, Nicolai P, et al. Carcinoma showing thymus-like differentiation (CASTLE) arising in the sublingual gland. Int J Surg Pathol. 2021;29:301–7.
14. Ge W, Yao YZ, Chen G, Ding YT. Clinical analysis of 82 cases of carcinoma showing thymus-like differentiation of the thyroid. Oncol Lett. 2016;11:1321–6.
15. Huang P, Huang R, Xiao W, Liu W, He T, Zhu W, et al. Ectopic thymic carcinoma in parotid gland: a rare case and review of literature. Int J Clin Exp Pathol. 2019;12:384–8.
16. Lorenz L, von Rappard J, Arnold W, Mutter N, Schirp U, Scherr A, et al. Pembrolizumab in a patient with a metastatic CASTLE tumor of the parotid. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.00734.
17. Kriegsmann M, Muley T, Harms A, Tavernar L, Goldmann T, Dienemann H, et al. Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases. Diagn Pathol. 2015;10:210.
18. Jha V, Sharma P, Mandal A. Utility of cluster of differentiation 5 and cluster of differentiation 117 immunoprofile in distinguishing thymic carcinoma from pulmonary squamous cell carcinoma: a study on 1800 non-small cell lung cancer cases. Indian J Med Paediatr Oncol. 2017;38:430–3.
19. Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, Tsuchiya R. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest. 2005;128:140–4.
20. Ambrosio MR, Mastrogiglio MG, Barone A, Rocca BJ, Gallo C, Lazzi S, et al. Lymphoepithelial-like carcinoma of the parotid gland: a case report and a brief review of the western literature. Diagn Pathol. 2013;8:115.
21. Ishikawa T, Ogawa T, Nakanome A, Yamauchi Y, Usubuchi H, Shiihara M, et al. Whole exome sequencing and establishment of an organoid culture of the carcinoma showing thymus-like differentiation (CASTLE) of the parotid gland. Virchows Arch. 2021;478:1149–59.
22. Bale PM, Sotelo-Avila C. Maldescent of the thymus: 34 necropsy and 10 surgical cases, including 7 thymuses medial to the mandible. Pediatr Pathol. 1993;13:181–90.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.